SCHEMBL427544

SCHEMBL427544

CN(C(=O)n1cnc(-c2cccc(OCc3ccccc3)c2)c1)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.46
CNR2 P34972 2/20 0.46
CHRNB2 P17787 3/20 0.40
CHRNB4 P30926 3/20 0.40
CHRNA3 P32297 3/20 0.40
CHRNA7 P36544 3/20 0.40
CHRNA4 P43681 3/20 0.40
CYP19A1 P11511 1/20 0.40
ADAM17 P78536 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
MAOB P27338 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
BRD4 O60885 1/20 0.39
CREBBP Q92793 1/20 0.39
EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425871 0.86 FAAH (0.51) FAAHCNR2MEN1LMNAALOX15
SCHEMBL427545 0.85 FAAH (0.47) FAAHCNR2MEN1LMNAALOX15
SCHEMBL427551 0.83 FAAH (0.42) FAAHMEN1LMNAALOX15TSHR
SCHEMBL425848 0.82 FAAH (0.41) FAAHMEN1LMNAALOX15TSHR
SCHEMBL526198 0.81 FAAH (0.58) FAAHCHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL14937606 0.80 KDM4E (0.51) FAAHKDM4EMEN1LMNAALOX15
SCHEMBL427136 0.79 USP2 (0.44) FAAHMEN1LMNAALOX15TSHR
SCHEMBL427564 0.78 FAAH (0.40) FAAHMEN1LMNAALOX15TSHR
SCHEMBL425928 0.78 TSHR (0.43) FAAHMEN1LMNAALOX15TSHR
SCHEMBL424646 0.78 USP2 (0.43) FAAHMEN1LMNAALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885CNR2 9/4885CHRNB2 2583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.